ClinicalTrials.gg
CompletedNCT03926182Updated Jan 6, 2020

Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers

A Phase 1 interventional study of AST2818 Tablets and AST2818 Tablets in Healthy Male Volunteers, sponsored by Allist Pharmaceuticals, Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-06.

Sponsored by Allist Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To assess the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers in Fasting State or Following a High Fat Meal

Read the detailed description

This is a single center, randomized, open label, single dose, two periods crossover study in healthy male volunteers. The volunteers will be randomly distributed into two groups (fasted-fed and fed-fasted groups). Any volunteer will be administrated once in each treatment period, the interval time of two treatment periods is 22 days (the interval time is no longer than 30 days).

02

Conditions studied

  • Healthy Male Volunteers
03

In context

Lead sponsor

Allist Pharmaceuticals, Inc. is the lead sponsor of 25 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male must be ≥ 18 and ≤ 55 years of age.
  2. Bodyweight of male must be ≥50.0kg and ≤80kg, and the must be ≥19.0 and ≤26.0 kg/m2.
  3. The results of previous medical history in screening period, physical examination, vital signs, blood and urine routine examination, blood biochemistry, chest X-ray and should compliance with the clinical protocol, or they will be recognized as non-clinical signs (NCS) if beyond the regulated range.
  4. The results of echocardiographic examination should meet the criteria that the value measured by biplane Simpson method was ≥ 50%.
  5. The participants must have no birthing plan and agree to take adequate non-drug measures within the study to 4 months after the last drug treatment.
  6. The participants have good communications with investigators, understand and comply with all requirements and fully understand and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. The participants have history of chronic disease and serious illness in vascular system, blood system, urinary system, respiratory system, digestive system, nervous system, skin system and psychiatric disorders, any conditions and illness threat to the health of participants, and the history of hereditary disease.
  2. The participants have history of similar drug, allergy history to similar drug, allergic disorders and allergic constitution.
  3. The participants having history of drug abuse,opioid and tranquillizer, drug addicts, or drug screening for someone was positive.
  4. Resting corrected using Fridericia's correction factor (QTcF) >470 msec within screening period.
  5. Any factors that increase the risk of prolonging QTc and abnormality in heart rate, i.e., heart failure, hypokalemia, congenital long QT syndrome, a family history of long QT syndrome or unreasonable sudden death at age smaller than 40 in first-degree relatives, administrating any combined medicines that possibly prolong QT interval
  6. Severe disease of respiratory system, i.e., interstitial lung disease and severe asthma, etc.
  7. Severe disease of ophthalmic system, e.g., corneal diseases;
  8. The participants have severe infection, severe trauma or major surgery within 1 year before screening;
  9. The participants have history of alcohol abuse (it was defined as that the daily alcohol consumption was higher than the following criteria: the weekly alcohol consumption was higher than 14 units of alcohol (1 unit= 360 ml beers/45 ml liquor containing 40% alcohol/150ml grape wine) 6 months prior to screening period, positive results of alcohol breath test and the volunteers who cannot give up drinking during study.
  10. The participants who smoked daily >5 sticks of cigarette 3 months prior to first dose or cannot give up smoking during study.
  11. The participants who have blood donation or excessive bleeding(>200ml) 3 months prior to first dose, and planned to donate blood or blood constituent.
  12. The participants who were taking any prescription medicine、 inducers/inhibitors within 1 month prior to first dose; any OTC, health care products (including vitamins), traditional chinese medicine within 2 weeks prior to screening period.
  13. The participants who participated other clinical trials and took the drug 3 months prior to first dose.
  14. The participants who have positive test result in , Anti-, Anti- and TPPA.
  15. Any condition affecting the drug taking, or affecting the oral absorption, include any kind of severe chronic gastroenteropathy, history of gastrointestinal resection or surgery, uncontrollable nausea or vomit, disability in swallowing.
  16. The participants who have history of needlesickness and blood phobia, and those with severe bleeding tendency.
  17. The participants who cannot comply with the roles of unified diet.
  18. The participants who cannot tolerate blood collection through venipuncture.
  19. The participants who have chronic overconsumption (> 8 cup one day, 1 cup=250 ml) of tea, coffee, and the drink with caffeine; or intake food or drink consist of any caffeine (i.e., coffee, strong tea, and chocolate );
  20. Any intake of drink or food, enriched in xanthine and grapefruit, that could affect the drug's absorption, distribution, metabolism and excretion.
  21. Any factors judged by investigator that the participants cannot meet.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Fasted AST2818 tablets following a period of fasting

    Drug: AST2818 Tablets

  • Experimental
    High-fat meal AST2818 tablets following a high-fat meal

    Drug: AST2818 Tablets

Interventions

  • AST2818 Tablets: Period 1 Fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once) and 4 hours after dosing on day 1. Period 2 Allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1.

  • AST2818 Tablets: Period 1 allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1. Period 2 fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once)and 4 hours after dosing on day 1.

06

What researchers measure

Primary outcomes

  1. Cmax of AST2818

    Pharmacokinetics of AST2818 by assessment of maximum plasma AST2818 concentration.

    Time frame: Blood samples collected on Day 1 at 0.5 hour of pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post AST2818 dose in each period of two groups.

  2. AUC(0-t) of AST2818

    Pharmacokinetics of AST2818 by assessment of area under the plasma concentration time curve from zero to appointed time

    Time frame: Blood samples collected on Day 1 at 0.5 hour of pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post AST2818 dose in each period of two groups.

  3. Tmax of AST2818

    Pharmacokinetics of AST2818 by assessment of time to Cmax.

    Time frame: Blood samples collected on Day 1 at 0.5 hour of pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post AST2818 dose in each period of two groups.

Secondary outcomes

  1. Cmax of AST5902

    Pharmacokinetics of AST5902 (metabolite to AST2818) by assessment of maximum plasma AST5902 concentration.

    Time frame: Blood samples collected on Day 1 at 0.5 hour of pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post AST2818 dose in each period of two groups.

  2. AUC(0-t) of AST5902

    Pharmacokinetics of AST5902 (metabolite to AST2818) by assessment of area under the plasma

    Time frame: Blood samples collected on Day 1 at 0.5 hour of pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post AST2818 dose in each period of two groups.

  3. Tmax of AST5902

    Pharmacokinetics of AST5902 (metabolite to AST2818) by assessment of time to Cmax.

    Time frame: Blood samples collected on Day 1 at 0.5 hour of pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post AST2818 dose in each period of two groups.

07

Study locations

1 site
  • Hunan Provincial Tumor Hospital
    Changsha, Hunan 410013, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Apr 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2019
First posted
Apr 24, 2019
StartActual
Feb 19, 2019
Primary completionActual
Apr 3, 2019
CompletionActual
Apr 3, 2019
Last update
Jan 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03926182
Responsible party
Sponsor
First posted
Apr 24, 2019
Start date
Feb 19, 2019
Primary completion
Apr 3, 2019
Completion
Apr 3, 2019
Last update
Jan 6, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflutinib

Start the discussion